The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 04, 2025

Filed:

Feb. 22, 2022
Applicant:

Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US);

Inventor:

Shunhai Wang, Ossining, NY (US);

Assignee:

Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07K 16/00 (2006.01); B01D 15/30 (2006.01); C07K 16/06 (2006.01); C12Q 1/6872 (2018.01); G01N 30/02 (2006.01); G01N 30/88 (2006.01); G01N 33/15 (2006.01); G01N 33/68 (2006.01);
U.S. Cl.
CPC ...
C07K 16/00 (2013.01); B01D 15/305 (2013.01); C07K 16/065 (2013.01); G01N 33/15 (2013.01); G01N 33/6857 (2013.01); C07K 2317/14 (2013.01); C07K 2317/41 (2013.01); C07K 2317/50 (2013.01); C07K 2317/515 (2013.01); C07K 2317/55 (2013.01); C07K 2319/00 (2013.01); C12Q 1/6872 (2013.01); C12Y 305/01052 (2013.01); G01N 2030/027 (2013.01); G01N 2030/8831 (2013.01); G01N 33/6848 (2013.01);
Abstract

Systems and methods for characterizing low molecular weight (LMW) protein drug product impurities are provided. One embodiment uses hydrophilic interaction chromatography (HILIC) coupled to mass spectrometry analysis. After removal of the N-linked glycans from the protein drug product, for example an antibody drug product, the elution of LMW impurities from the HILIC column was determined by the size of the molecular weight species. In some embodiments, the HILIC separation is performed under denaturing conditions, making the detection of LMW forms using this method highly comparable to both SDS-PAGE and CE-SDS methods. LMW drug product impurities include, but are not limited to light chain, half antibody, H2L, H2, HL, HC, peptide backbone-truncated species, and combinations thereof.


Find Patent Forward Citations

Loading…